Using ctDNA methylation to guide chemotherapy for high-risk colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of adjuvant chemotherapy guided by circulating tumor DNA (ctDNA) methylation levels in patients with high-risk stage II and III colorectal cancer. Patients who have undergone surgery for colorectal adenocarcinoma and tested positive for ctDNA methylation will receive either mFOLFIRINOX or mFOLFOX6/XELOX chemotherapy regimens. The study aims to improve postoperative outcomes and reduce recurrence rates in this high-risk population. By tailoring chemotherapy based on ctDNA status, the trial seeks to enhance treatment efficacy and patient survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients who have been histopathologically diagnosed with colorectal adenocarcinoma;

Patients who have undergone radical curative resection of the primary tumors;

Patients with CRC of high-risk stage II and stage III based on final findings (UICC TNM Classification, 8th Edition);

Patients who tested positive for ctDNA methylation at 5-7 days after surgery prior to enrollment;

Patients with no obvious relapse confirmed by chest, abdominal, and pelvic CT scans, etc.;

Patients aged ≥ 18 and ≤80 years old, regardless of gender;

Patients with expected survival of more than 12 months;

Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;

Patients who have no severe disorder in major organs (such as the bone marrow, heart, lungs, liver, and kidneys) and meet the following criteria: Neutrophil count ≥ 1,500/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8.0 g/dL, Serum creatinine ≤ 1.5 mg/dL, Total bilirubin ≤ 1.5 mg/dL, ALT and AST ≤ 100 U/L

Patients with no diarrhea or stomatitis of Grade 2 or severer according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0;

Patients who voluntarily gave written consent to participate in the trial after receiving a thorough explanation of the trial before enrolling in the trial

Exclusion Criteria:

Neoadjuvant therapy performed before operation;

Blood transfusion performed during operation or within 2 weeks before operation;

Incomplete baseline samples, including preoperative plasma samples and plasma samples 5-7 days after operation;

Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;

Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;

Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;

Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;

Significant impairment of important organ function;

Other conditions in which the investigator believes that the patient should not participate in this trial

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Active surveillance after immunotherapy for MMR-deficient colorectal and GI cancers

  This study looks at whether some patients with non-metastatic, MMR-deficient or MSI-H colorectal cancers can skip surgery after a strong response to immunotherapy.

  Recruiting at 3 sites University Hospital, Basel, Switzerland · Basel and 2 other locations · NCT07829081

• Using fluorescence imaging and light therapy to improve surgery outcomes for advanced colorectal cancer

  This study is testing if using special light to help surgeons see cancer better during surgery, followed by light therapy to kill leftover cancer cells, can improve outcomes for people with advanced colorectal cancer.

  Recruiting Phase 1/2 Roswell Park Cancer Institute · Buffalo, New York · NCT06307548

• Monitoring tumor DNA methylation after surgery for colorectal cancer

  This study is testing if checking for tumor DNA in the blood after surgery can help doctors better monitor recovery and spot any signs of colorectal cancer coming back in patients who are at high risk.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT05904665

• Using Thymosin-alpha 1 to prevent cancer recurrence after surgery for high-risk colorectal cancer

  This study is testing if a drug called thymosin-alpha 1 can help prevent cancer from coming back in people with high-risk colorectal cancer after their surgery.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05086614

• Testing stool samples for cancer detection in colorectal cancer survivors

  This study is testing if a new stool test can help find polyps and cancer in colorectal cancer survivors to see if it works better than regular check-ups.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT04624555

• Exploring how exercise affects cancer recurrence

  This study is testing how different levels of aerobic exercise can help reduce the chances of cancer coming back in people who have been treated for breast, prostate, or colorectal cancer.

  Recruiting City of Hope Medical Center · Durate, California and 8 other locations · NCT04589468

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.